Neonatal sepsis, a condition caused by the body’s response to infections, affects four million newborns globally every year. It makes up 15% of all neonatal deaths and the majority occur in low-income countries. Alarmingly, and further complicating an already lethal condition, up to 40% of neonatal sepsis cases are due to resistant pathogens. Today, on World Children's Day, ReAct releases a new report on newborns, sepsis and antibiotic resistance.
Over 400 responses from 74 countries
ReAct conducted a web-based survey between July 29th – October15th, 2020 aiming to understand the awareness, availability of guidelines, general practice and potential challenges physicians face around neonatal sepsis and antimicrobial resistance. Over 400 responses from 74 countries were received.
- Overall, 60% of respondents are very or even extremely worried about antimicrobial resistance as a threat to the effective treatment of neonatal sepsis.
- 79% of respondents have seen an increasing trend of multidrug resistant infections over the last five years, regardless of the region and income level of the health care facility where they work.
- In some low-income countries, physicians report that over 50% of the newborns they treat develop sepsis and that over 75% of neonatal sepsis cases are due to resistant pathogens.
More news and opinion
- ReAct Asia Pacific: Winners of 2020 photography competition
- WAAW ReAct Africa: Engaging civil society and students
- WAAW in Indonesia: Focus on One Health approach to AMR
- Innovate4Health’s 32 finalist teams: For social innovations to address emerging infectious diseases!
- ReAct Open Letter: 5 key points to One Health Global Leaders Group on Antimicrobial Resistance
- New ReAct Report: Treatment of newborn sepsis is threatened – effective antibiotics essential
- Upcoming ReAct Africa Conference: What is the status of the NAPs on AMR in the African region?
- Animal welfare and antibiotic resistance in food animals
- ReAct activities for World Antimicrobial Awareness Week 2020
- Dr. Honar Cherif: My patients can recieve 5-10 courses of antibiotics during their cancer treatment
- New ReAct Report: Antibiotic resistance affects men and women differently
- ReAct Asia Pacific: Photo competition for students – health in focus
- 4 take aways from WHO’s first global report on sepsis
- Launch of global student design sprint – Innovate4Health
- World Sepsis Day – antibiotics essential in treatment of sepsis
- The new Pharmaceutical Strategy for Europe – an opportunity to put public interest first
- 4 key reflections on the recently launched WHO GLASS-report
- Key points from ReAct’s comments to the Independent Panel on Evidence
- ReAct Interview: From zoologist to community engagement on AMR
- ReAct Africa expands
- COVID-19 resolution – a missed opportunity to address global pandemic response more broadly
- What everyone needs to know about clinical research
- New ReAct Policy Brief: Successful cancer treatment relies on effective antibiotics
- Impact of COVID-19 on vaccine-preventable diseases and antibiotic resistance
- ReAct Africa and Africa CDC: COVID-19 webinars
- Antibiotic pollution: India scores a global first with effluent limits
- COVID-19 and AMR – what do we know so far?
- Learning from bedaquiline in South Africa – comprehensive health systems for new antibiotics
- ReAct Interview: How does antibiotics in food animal production end up in the environment?
- Key take aways from CSO workshop on AMR in Kenya
- New fact sheet: Effective antibiotics – essential for childrens’ survival
- Shortages and AMR – why should we care? 4 consequences of antibiotic shortages
- Our microbiome and noncommunicable diseases
- The 2020 AMR Benchmark Report – concerning findings with questionable framing
- 4 key reflections from engaging hospitals in India for antibiotic stewardship
- Teacher Gustavo Cedillo, Ecuador, teaches children about the bacterial world